Aveanna Healthcare Holdings, Inc. (AVAH)
NASDAQHealth CareMedical - Care FacilitiesSnapshot 2026-09-04
$13.58-0.44%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Care FacilitiesSnapshot 2026-09-04
Intact: The reason to own it still holds.
Aveanna Healthcare grows revenue about 7% to $2.64 billion in 2026. Profit rises with adjusted EBITDA near $340 million. The Family First acquisition expands services and supports growth. The stock trades cheap versus peers with a PE of 14.5.
Growth could slow if integration of Family First fails. Profit margins might shrink below 31.7%. The healthcare sector's risks and elevated company risk could pressure results.
The price is about 1% below our fair value near $9.66. Analysts expect about 8% revenue growth, which aligns with management guidance. Our view is in line with the Street.
Breaks if: Adjusted EBITDA falls below $328 million in FY26
Breaks if: Acquisition fails to contribute to revenue growth or causes operational issues
Breaks if: Gross margin falls below 30% in FY26
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
AVAH represents a durable compounder with a focus on growth through acquisitions and operational improvements. The current thesis state is intact, supported by strong recent financial performance and management's commitment to increasing revenue and EBITDA guidance.
The market appears to be pricing in a neutral valuation, with some expectations of growth but also acknowledging the fragility in execution quality. AVAH is seen as cheap compared to peers, but there is a notable expectations gap that suggests some caution.
Fundamentals are likely to continue improving, given management's strong focus on revenue and EBITDA growth. However, there is a medium confidence level in earnings quality, which introduces some risk, especially considering the company's recent history of performance misses.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. The company raised its revenue guidance for 2026. This suggests stronger future performance. However, a secondary offering may dilute shareholder value. This could affect capital structure negatively.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: Revenue falls below $2.56 billion in FY26
The thesis hinges on management's ability to maintain guidance and deliver on growth targets. Additionally, the performance of sector bellwethers and overall economic conditions, such as job growth, will significantly impact AVAH's trajectory.
Overall, AVAH's performance and strategic direction appear solid for the next 1 to 3 years, but risks remain elevated. Not investment advice.